---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-034965"
form_type: "8-K"
ticker: "PLSH"
cik: "0001552189"
company_name: "PANACEA LIFE SCIENCES HOLDINGS, INC."
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:21:02.552286+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Panacea Life Sciences acquires PUR Life Medical franchise for $1M cash plus up to $1.6M contingent

## Summary
- Purchase price of $1M cash plus up to $1.6M payable over 4 years based on franchise fee and royalty collection.
- Cash due in two tranches: $180,000 upon receipt of auditable financials and $820,000 on November 10, 2023.
- Founder Dan Olsen (58.5% owner of PUR Life) retains 7% of new subsidiary; Panacea holds 93%.
- Acquisition adds 60+ franchise locations, alternative medicine and pain management services to Panacea's vertical integration.
- Panacea plans to finance the cash portion through debt and equity.

## SEC filing metadata
- accession: 0001493152-23-034965
- form_type: 8-K
- ticker: PLSH
- cik: 0001552189
- company_name: PANACEA LIFE SCIENCES HOLDINGS, INC.
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1552189/000149315223034965/0001493152-23-034965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1552189/000149315223034965/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-034965
- JSON: https://secwatch.observer/filing/0001493152-23-034965.json
- Plain text: https://secwatch.observer/filing/0001493152-23-034965.txt

## Key facts
- Material Agreements
  PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Asset Purchase Agreement with PUR Life Medical, Inc. valued at $180,000 (effective 2023-09-26).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: PUR Life Medical, Inc.
  - Value: $180,000
  - Effective: 2023-09-26
  source text: On September 26, 2023, Panacea Life Sciences Holdings, Inc. (the “Company,” “Panacea,” “we,” or “our”) and PUR Life Medical, Inc. (“PUR Life”) entered into an Asset Purchase Agreement (“APA”) pursuant to which PUR Life agreed to sell and Panacea agreed to purchase all of the following assets
  evidence_url: https://www.sec.gov/Archives/edgar/data/1552189/000149315223034965/0001493152-23-034965-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.